Kairos Pharma reported cash from operations of -$0.81M and free cash flow of -$0.81M for the quarter ended Jun 2025, down 379.2% year over year. This cash flow statement covers 8 quarters of results from Sep 2023 through Jun 2025, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -0.30M | -1.09M | -0.30M | -0.23M | -0.92M | -1.58M | -1.26M | -1.42M |
| Gains from Investment SecuritiesGains Investment | 0.03M | |||||||
| Cash from OperationsCash from Ops. | 0.07M | 0.04M | -0.17M | -2.02M | -1.80M | -0.71M | -0.81M | |
| Depreciation, Depletion & Amortization | ||||||||
| Amortizatization of IntangiblesAmort. of Intangibles | 0.01M | 0.03M | 0.02M | 0.12M | ||||
| Change in Working Capital | ||||||||
| Change in Accured ExpensesChange Accured Exp. | 0.20M | 0.31M | 0.02M | -0.19M | 0.26M | -0.19M | -0.13M | |
| Financing Activities | ||||||||
| Other financing activitiesOther financing | 0.07M | 0.09M | -0.05M | 0.03M | 3.06M | |||
| Cash from Financing ActivitiesCash from Financing | -0.07M | -0.09M | 0.15M | 5.22M | -0.14M | 3.06M | 0.22M | |
| Additional items | ||||||||
| Change in Cash | -0.01M | -0.05M | -0.02M | 3.20M | -1.95M | 2.34M | -0.58M | |
| Free Cash FlowFCF | 0.07M | 0.04M | -0.17M | -2.02M | -1.80M | -0.71M | -0.81M | |
| Net Cash FlowNCF | -0.01M | -0.05M | -0.02M | 3.20M | -1.95M | 2.34M | -0.58M |